Clinical Trial

Native Coronary Artery Instead of SAphenous Vein Graft Intervention for Treatment of Significant Saphenous Vein Graft Lesions

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The primary study objective of the NASA registry is to evaluate the 12-month incidence of target vessel failure (TVF) in patients who present with saphenous vein graft (SVG) lesions and undergo percutaneous coronary intervention (PCI) of the corresponding native coronary artery.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-12-28; most recent amendment 2025-01-22.
Status change: Recruiting → Active, Not Recruiting 2025-01-22
Trial Details
NCT Number NCT05187351
Lead Sponsor Minneapolis Heart Institute Foundation
Conditions Target Vessel Failure in Saphenous Vein Grafts, Percutaneous Coronary Intervention
Enrollment 99 participants
Start Date 2021-11-21
Primary Completion 2030-01 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-27